{"id":5135,"date":"2020-10-14T12:03:17","date_gmt":"2020-10-14T10:03:17","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/?p=5135"},"modified":"2020-10-14T12:04:40","modified_gmt":"2020-10-14T10:04:40","slug":"inside-stayble-oktober-2020","status":"publish","type":"post","link":"https:\/\/staybletherapeutics.com\/sv\/presentationer\/inside-stayble-oktober-2020\/","title":{"rendered":"Inside Stayble: Oktober 2020"},"content":{"rendered":"<p>I oktober 2020 uppdateringen g\u00e5r VD Andreas Gerward igenom framstegen i kliniska fas IIb-studien med STA363, vikten av att delta i Eurospine kongresssen, rekryteringsprocessen av CCO, kommande investerartr\u00e4ffar \u2013 och mer.<\/p>\n<p>Inside Stayble \u00e4r en ny kommunikationskanal f\u00f6r att ge aktie\u00e4gare m\u00e5nadsvisa uppdateringar om Stayble Therapeutics och det kliniska utvecklingsprogrammet f\u00f6r STA363 i kronisk l\u00e4ndryggssm\u00e4rta.<\/p>\n<p>Stayble \u00e4r listat p\u00e5 Nasdaq First North (STABL).<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>I oktober 2020 uppdateringen g\u00e5r VD Andreas Gerward igenom framstegen i kliniska fas IIb-studien med STA363, vikten av att delta i Eurospine kongresssen, rekryteringsprocessen av CCO, kommande investerartr\u00e4ffar \u2013 och mer.<\/p>\n","protected":false},"author":1,"featured_media":5136,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts\/5135"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5135"}],"version-history":[{"count":3,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts\/5135\/revisions"}],"predecessor-version":[{"id":5139,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts\/5135\/revisions\/5139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media\/5136"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/categories?post=5135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/tags?post=5135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}